Kidney Fibrosis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H2 2016, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 21 and 7 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively for Kidney Fibrosis.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Kidney Fibrosis Overview 10
Therapeutics Development 11
Pipeline Products for Kidney Fibrosis - Overview 11
Pipeline Products for Kidney Fibrosis - Comparative Analysis 12
Kidney Fibrosis - Therapeutics under Development by Companies 13
Kidney Fibrosis - Therapeutics under Investigation by Universities/Institutes 15
Kidney Fibrosis - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Kidney Fibrosis - Products under Development by Companies 18
Kidney Fibrosis - Products under Investigation by Universities/Institutes 20
Kidney Fibrosis - Companies Involved in Therapeutics Development 21
AbbVie Inc 21
Angion Biomedica Corp. 22
Bio-inRen 23
BiOrion Technologies B.V. 24
Cellmid Limited 25
Epigen Biosciences, Inc. 26
Evotec AG 27
Galectin Therapeutics, Inc. 28
GenKyoTex S.A. 29
Intercept Pharmaceuticals, Inc. 30
Isarna Therapeutics GmbH 31
Lpath, Inc. 32
MorphoSys AG 33
Pharmaxis Limited 34
ProMetic Life Sciences Inc. 35
Raptor Pharmaceutical Corp. 36
Regulus Therapeutics Inc. 37
Symic Biomedical, Inc. 38
Tobira Therapeutics, Inc. 39
Vascular Biogenics Ltd. 40
Kidney Fibrosis - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
ANG-3070 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ANG-3586 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ANG-4021 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
BOT-191 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
BRN-1889 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
CAB-102 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
cenicriviroc mesylate - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
CT-140 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
cysteamine DR - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Drugs for Tissue Fibrosis - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
GKT-136901 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
GRMD-02 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
ICG-001 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
INT-767 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
ISTH-0047 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
LJ-1888 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
Lpathomab - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
melittin - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
MOR-107 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
P-007 - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
PBI-4050 - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
PBI-4419 - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
PXS-4820 - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
PXS-5033A - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
RG-012 - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
SB-300 - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
SOL-1 - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
VB-703 - Drug Profile 121
Product Description 121
Mechanism Of Action 121
R&D Progress 121
Kidney Fibrosis - Dormant Projects 122
Kidney Fibrosis - Product Development Milestones 123
Featured News & Press Releases 123
Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis 123
Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics 123
Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting 124
Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015 125
Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases 127
Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting 127
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 128
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 128
Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting 129
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 130
Disclaimer 131

List of Tables

Number of Products under Development for Kidney Fibrosis, H2 2016 11
Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2016 20
Kidney Fibrosis - Pipeline by AbbVie Inc, H2 2016 21
Kidney Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016 22
Kidney Fibrosis - Pipeline by Bio-inRen, H2 2016 23
Kidney Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016 24
Kidney Fibrosis - Pipeline by Cellmid Limited, H2 2016 25
Kidney Fibrosis - Pipeline by Epigen Biosciences, Inc., H2 2016 26
Kidney Fibrosis - Pipeline by Evotec AG, H2 2016 27
Kidney Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016 28
Kidney Fibrosis - Pipeline by GenKyoTex S.A., H2 2016 29
Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 30
Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016 31
Kidney Fibrosis - Pipeline by Lpath, Inc., H2 2016 32
Kidney Fibrosis - Pipeline by MorphoSys AG, H2 2016 33
Kidney Fibrosis - Pipeline by Pharmaxis Limited, H2 2016 34
Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016 35
Kidney Fibrosis - Pipeline by Raptor Pharmaceutical Corp., H2 2016 36
Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc., H2 2016 37
Kidney Fibrosis - Pipeline by Symic Biomedical, Inc., H2 2016 38
Kidney Fibrosis - Pipeline by Tobira Therapeutics, Inc., H2 2016 39
Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd., H2 2016 40
Assessment by Monotherapy Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 46
Number of Products by Stage and Route of Administration, H2 2016 49
Number of Products by Stage and Molecule Type, H2 2016 51
Kidney Fibrosis - Dormant Projects, H2 2016 122